Price Gap Between Brand And Generic Drugs Widening – Express Scripts
This article was originally published in The Pink Sheet Daily
In its inaugural Drug Trends Quarterly, Express Scripts finds that prices for branded pharmaceuticals are growing at a faster pace than the Consumer Price Index and the gap between branded and generic drug prices is at its widest point since the pharmacy benefit manager began calculating price indexes for each in 2008.
You may also be interested in...
Analysts reporting in the American Journal of Health-System Pharmacy are predicting that across all settings, pharmaceutical expenditures are expected to rise 1%-3% across all settings, with expenditures in the clinic setting increasing 2%-4%. In hospitals, the expected range is from a potential decrease of 0.5% to an increase of 1.5%.
The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.
In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.